GSK acquires RAPT Therapeutics

GSK agreed to acquire RAPT Therapeutics. Reported deal value: $2.2B. Status: Pending. Sector: biopharmaceutical. Target headquarters context: South San Francisco, California, United States.

This page summarizes publicly available information about the transaction as of 2026-01-20. Figures and status may change as filings and press coverage update.

GSK to Bolster Immunology Pipeline With $2.2 Billion Rapt Therapeutics Acquisition GSK signed a definitive agreement to purchase US-based clinical-stage biopharmaceutical company Rapt Therapeutics for a total equity value of $2.2 billion, fortifying its respiratory, immunology,